# Janux Therapeutics, Inc.: overview

JANX · Nasdaq · CIK 1817713 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/janx.md) · [Financials](/companies/janx/financials.md) · [Filings](/companies/janx/filings.md) · [Insiders](/companies/janx/insiders.md)

Latest reported revenue: [$10.3m](/filings/0001193125-26-338078.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-338078).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001193125-25-269799.md) | [0.0 d](/filings/0001193125-26-076918.md) | [0.0](/filings/0001193125-26-212146.md) | [0.0](/filings/0001193125-26-338078.md) | [10.0](/filings/0001193125-25-269799.md) | [0.0 d](/filings/0001193125-26-076918.md) | [3.7](/filings/0001193125-26-212146.md) | [10.3](/filings/0001193125-26-338078.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8164.5%)](/filings/0001193125-25-269799.md) | not reported | not reported | not reported | [(352.5%)](/filings/0001193125-25-269799.md) | not reported | [(916.5%)](/filings/0001193125-26-212146.md) | [(308.7%)](/filings/0001193125-26-338078.md) |
| Net margin | % | [(6391.6%)](/filings/0001193125-25-269799.md) | not reported | not reported | not reported | [(243.1%)](/filings/0001193125-25-269799.md) | not reported | [(652.6%)](/filings/0001193125-26-212146.md) | [(214.0%)](/filings/0001193125-26-338078.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001193125-25-269799.md) | not reported | [(0.38)](/filings/0001193125-26-212146.md) | [(0.55)](/filings/0001193125-26-338078.md) | [(0.39)](/filings/0001193125-25-269799.md) | not reported | [(0.39)](/filings/0001193125-26-212146.md) | [(0.35)](/filings/0001193125-26-338078.md) |
| Free cash flow | $m | [(2.3) d](/filings/0001193125-25-269799.md) | [(16.8) d](/filings/0001193125-26-076918.md) | [(17.4)](/filings/0001193125-26-212146.md) | [(24.3) d](/filings/0001193125-26-338078.md) | [(12.9) d](/filings/0001193125-25-269799.md) | [(28.6) d](/filings/0001193125-26-076918.md) | [(12.6)](/filings/0001193125-26-212146.md) | [12.3 d](/filings/0001193125-26-338078.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.6](/filings/0000950170-23-007311.md) | [8.6](/filings/0000950170-25-029177.md) | [8.1](/filings/0001193125-26-076918.md) | [10.6](/filings/0001193125-26-076918.md) | [10.0](/filings/0001193125-26-076918.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(905.4%)](/filings/0000950170-23-007311.md) | [(779.0%)](/filings/0000950170-25-029177.md) | [(902.9%)](/filings/0001193125-26-076918.md) | [(933.6%)](/filings/0001193125-26-076918.md) | [(1576.7%)](/filings/0001193125-26-076918.md) |
| Net margin | % | [(898.3%)](/filings/0000950170-23-007311.md) | [(732.2%)](/filings/0000950170-25-029177.md) | [(721.2%)](/filings/0001193125-26-076918.md) | [(651.6%)](/filings/0001193125-26-076918.md) | [(1136.3%)](/filings/0001193125-26-076918.md) |
| Diluted EPS | $ per share | [(1.39)](/filings/0000950170-23-007311.md) | [(1.52)](/filings/0000950170-25-029177.md) | [(1.32)](/filings/0001193125-26-076918.md) | [(1.28)](/filings/0001193125-26-076918.md) | [(1.83)](/filings/0001193125-26-076918.md) |
| Free cash flow | $m | [(18.5)](/filings/0000950170-23-007311.md) | [(49.4)](/filings/0000950170-25-029177.md) | [(52.4)](/filings/0001193125-26-076918.md) | [(44.2)](/filings/0001193125-26-076918.md) | [(83.3)](/filings/0001193125-26-076918.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/janx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $171.9m | 11,189,693 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $94.2m | 6,134,667 |  | Added +701,434 |
| [Prosight Management, LP](/funds/1617201.md) | 2026-06-30 | $58.4m | 3,804,481 |  | Added +254,481 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $58.3m | 4,196,409 |  | Not compared |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $46.2m | 3,004,899 |  | Added +540,882 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $37.1m | 2,412,825 |  | Reduced −122,899 |
| [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $36.1m | 2,352,927 |  | Added +2,298,727 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $30.6m | 1,993,837 |  | Added +837,697 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $28.5m | 1,857,351 |  | Added +45,986 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $27.5m | 1,789,617 |  | Unchanged |

## Recent filings

[All 436 filings](/companies/janx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:18 ET | [10-Q](/filings/0001193125-26-338078.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338078 |
| 2026-08-06 | 16:08 ET | [8-K](/filings/0001193125-26-337977.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337977 |
| 2026-06-23 | 16:05 ET | [8-K](/filings/0001193125-26-279428.md) | 8.01 Other events | 0001193125-26-279428 |
| 2026-06-12 | 16:06 ET | [8-K](/filings/0001193125-26-269387.md) | 5.07 Shareholder vote results | 0001193125-26-269387 |
| 2026-05-07 | 16:33 ET | [10-Q](/filings/0001193125-26-212146.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212146 |
| 2026-05-07 | 16:16 ET | [8-K](/filings/0001193125-26-211964.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211964 |
| 2026-04-28 | 17:02 ET | [8-K](/filings/0001193125-26-187641.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-187641 |
| 2026-04-28 | 16:15 ET | [DEF 14A](/filings/0001193125-26-187095.md) | Proxy statement, period 2026-06-11 | 0001193125-26-187095 |
| 2026-02-26 | 16:32 ET | [10-K](/filings/0001193125-26-076918.md) | Annual report, period 2025-12-31 | 0001193125-26-076918 |
| 2026-02-26 | 16:10 ET | [8-K](/filings/0001193125-26-076627.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076627 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076918.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7f2c1462-a2c1-42a5-8a4f-de2194ec8ac6)

## About the filer

- CIK: 1817713
- Tickers: JANX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.